Dr Moyle’s laboratory (www.moylelab.com) uses cutting edge technologies for the synthesis of peptides, protein expression, and protein semi-synthesis to gain insights into the functional roles played by various biochemical pathways, to engineer better protein and peptide therapeutics, and to improve the delivery characteristics of various therapeutic molecules. Specific current areas of interest are detailed below:
Subunit Vaccine Development: methods to develop improved vaccines through the combination of recombinant and synthetic approaches to improve immunopotency and tailor immune responses (links to reseach articles on semisynthetic vaccines and peptide vaccines; reviews on vaccine development).
Delivery Systems for Nucleic Acid-Based Molecules: multi-component synthetic and recombinant approaches to improve the cellular uptake, and targeted delivery of various oligonucleotide molecules (e.g. siRNA, mRNA, pDNA and CRISPR-Cas9) as an exciting approach to treat or prevent various diseases (links to research articles and reviews).
Deciphering the Roles of Post-Translational Modifications: The combination of peptide synthesis and protein semisynthesis to enable the production of large amounts of site-specifically modified species, that can be used to deconvolute the roles played by various post-translational modifications (links to research articles).
Peptide/Protein Drugs and Delivery: The study of methods to improve the delivery characteristics of peptide/protein drugs (e.g. poor oral absorption, instability to chemical/enzymatic degradation, and the inability to reach their site/s of action) through chemical engineering approaches.
New Approaches for Superbugs: the development of antivirulence approaches, and formulations (e.g. various types of nanoparticles - silver, protein, mesoporous silica), which reduce the ability for microbes to cause disease, and make them more readily treated with antimicrobials, by providing access to synergistic combinations, and reducing the risk of antimicrobial resistance.
Information for Potential Students:
The Moyle lab considers applications from potential students and postdoctoral fellows with an interest in: i)infection control (including subunit vaccine and antimicrobial development); ii)delivery systems for peptide therapeutics; iii)targeted delivery systems; iv) studying the function of posttranslational modifications; and v) delivery systems for nucleic acid-based therapeutics (e.g. siRNA, shRNA, miRNA, mRNA, pDNA and CRISPR-Cas9). If you are interested in working in any of these areas please feel free to contact Dr Moyle (p.moyle@uq.edu.au). Please ensure that you supply an up to date CV; describe why you would like to work in the Moyle lab; provide a listing of publications (preferably with impact factors and citation counts); and indicate what skills you would bring to the lab. Detailed information on our laboratory is available at www.moylelab.com. Preference will be given to students and postdoctoral fellows who have their own funding.
Dr Moyle Biosketch:
Dr Moyle (H-index 30, >2600 citations; >95 publications; 13/8/2024; Google Scholar, ORCID, ResearcherID, and Publons profiles) received a PhD (Dec 2006) and a Bachelor of Pharmacy (Hons I) (Dec 2001) from The University of Queensland (UQ); graduated from the Pharmaceutical Society of Australia pre-registration pharmacist-training course (Nov 2002); and is registered with the Pharmacy Board of Australia. He currently works as an Associate Professor in the UQ School of Pharmacy, where he has been based since 2014.
Dr Moyle works in the fields of medicinal chemistry, chemical biology, and drug formulation, investigating subunit vaccine development, outcomes associated with histone post-translational modifications, and methods to improve the delivery characteristics of oligonucleotide (e.g. siRNA and pDNA), peptide, and protein therapeutics. During his PhD, Dr Moyle developed methods that enabled the synthesis of pure, lipid adjuvanted peptide vaccines, using advanced chemical ligation techniques. In addition, the conjugation of mannose to combined prophylactic/therapeutic human papillomavirus type-16 vaccines, to target dendritic cells, was demonstrated to significantly improve vaccine anti-tumour activity. This work, conducted with leading researchers at the QIMR Berghofer Medical Research Institute (Prof Michael Good & Dr Colleen Olive), established Dr Moyle’s national and international profile in the field of vaccine development, resulting in 11 peer reviewed papers, including top journals in the field (J Med Chem; J Org Chem), as well as 6 review articles and 2 invited book chapters.
Dr Moyle undertook his postdoctoral training in the laboratory of one of the world’s premier chemical biologists, Professor Tom Muir (the Rockefeller University, NY, USA; now at Princeton University, NJ, USA). During this time he developed an extensive knowledge of techniques for protein expression, bioconjugation, bioassays, and proteomics, which represent an essential skill set required for this proposal. As part of this work, Dr Moyle developed novel synthetic routes to generate site-specific ADP-ribose conjugated peptides and proteins. This research was hailed as a major breakthrough in the field, leading to several collaborations, and an exemplary publication in the prestigious chemistry journal JACS. This vast body of work identified the enzyme (PARP10) responsible for mono-ADP-ribosylation of histone H2B, and demonstrated interactions between this modification and several proteins, including BAL, which is associated with B cell lymphomas. In addition, a number of robust chemical methods were developed to enable the synthesis of a complete library of methyl-arginine containing histones, which were incorporated into synthetic chemically-defined chromatin to investigate the site-specific effects of arginine methylation on histone acetylation. This work led to a collaboration with colleagues at Rockefeller to investigate the effects of histone arginine methylation on transcription.
Teaching:
Dr Moyle teaches into the following subjects in the UQ School of Pharmacy.
PHRM3011 (Quality Use of Medicines) - course coordinator
PHRM4021 (Integrated Pharmaceutical Development)
PHRM3021 (Dosage Form Design)
PHRM2040 (Drug Discovery)
Awards:
2016 - Health and Behavioural Sciences (HABS) faculty commendation for Early Career Citations for Outstanding Contributions to Student Learning (ECCOSL)
2015 - ChemMedChem top 10 cited article of 2013 (link)
2014 - Highest ranked NHMRC development grant (2013; APP1074899)
2013 - Institute for Molecular Biology (IMB) Division of Chemistry and Structural Biology Prize
Michael has over 30 years’ experience in clinical medicine (infectious diseases & paediatrics) and clinical laboratory microbiology with a particular interest in the epidemiology of vaccine preventable diseases and the diagnosis of infectious diseases in hospital, public health and industry settings. He recently took up the inaugural Director of Research at The Prince Charles Hospital in Brisbane.
He is a past Principal Medical Officer and Director of CoVID-19 Pharmacovigilance at the Therapeutic Goods Administration, Department of Health & Ageing, Australian Government (2021-2022), Director of Scientific Affairs & Public Health for GSK Vaccines in the Greater China Intercontinental region based in Singapore (2014-2020) and Director of Infectious Diseases at the Royal Children’s Hospital-Brisbane and a practising Clinical Microbiologist at the Royal Brisbane & Women’s Hospitals (2000-2014). Michael is a past full member of the Australian Technical Advisory Group for Immunisation from 2007 to 2013.
Prof. Nissen has 223 peer-reviewed medical publications and book chapters, a h- index of 64 with 13,321 citations of his work to date. His research interests include the epidemiology and prevention of vaccine preventable diseases and the rapid molecular diagnostic techniques of infectious diseases.
Professor Obermair is the Director of Queensland Centre for Gynaecological Cancer Research (QCGC Research). He is a Professor of Gynaecological Oncology since 2007, a Senior Medical Officer at Royal Brisbane & Women’s Hospital and a Visiting Medical Officer at St Andrews War Memorial Hospital and Buderim Private Hospital. He holds an Honorary title of Professor at UQ since 2006.
Professor Obermair is an internationally recognised leader in gynaecological oncology research and treatment and has lead the research team at QCGC Research since establishing it in 2003.
I began my career working in industry for a company which specialised in in vitro diagnostic assays, for both human and veterinary health (AGEN Biomedical). There, I worked as a scientist for almost a decade in numerous departments of the commercialisation pipeline, including manufacturing, product development and research. Following this, I completed a PhD (2010) with the Australian Biosecurity Co-operative Research Centre for Emerging Infectious Disease and have since worked as a virologist at The University of Queensland.
My current research focuses on mosquito-borne virus discovery and the development of innovative vaccine and diagnostic platforms. Together, these research interests have culminated in a greater understanding of the mosquito virome and the development of new approaches for the detection of novel viruses. These include high throughput sequence and antigen-independent assays and the development of suites of unique monoclonal antibodies (mAbs), which in conjunction with deep sequencing platforms, provide comprehensive virus discovery strategies. Using this repertoire, I have been involved in the discovery and extensive genetic and phenotypic characterisation of new mosquito-borne viruses, belonging to more than six viral taxon (including Flaviviridae, Mesoniviridae, Bunyavirales, Reoviridae, Negevirus, Nodaviridae).
Harnessing the unique mosquito-specific growth restriction of the insect-specific flaviviruses that we discovered, my research now focuses on the application of these viruses to the development of novel, safe vaccines and diagnostics for multiple pathogenic flaviviruses.
I got my BSc degree from the University of Natural Sciences in Vietnam. I spent the next two years working on characterisation of multi-drug resistant Mycobacterium tuberculosis with Dr Maxine Caws at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. I went to the Wellcome Trust Sanger Institute and the University of Cambridge, UK to do my PhD in Prof. John Wain lab where I studied molecular mechanisms affecting the stability of IncHI1 multidrug resistant plasmids in Salmonella Typhi. I then moved to Australia to join the group of Prof. Mark Schembri at the School of Chemistry and Molecular Biosciences, University of Queensland. I am now working on identifying novel virulent factors in uropathogenic E. coli, especially in the newly emerged but globally spread ST131 clone, using high-throughput transposon mutagenesis and next-gen sequencing. I also maintain my interest in plasmid biology and have started projects to study multidrug resistant plasmids carrying blaCTX-M-15 or blaNDM-1 resistant genes.
Professor Mark Schembri is a prominent microbiologist with experience in combating the global health crisis presented by multi-drug resistant pathogens. Professor Schembri’s expertise on the virulence of bacterial pathogens and his innovative analysis of biofilm formation aims to improve the outcomes of the >400 million individuals that suffer from urinary tract infections each year across the globe.
Through the application of genetic, genomic and functional studies on uropathogenic E. coli, Professor Schembri has identified targets to reduce the virulence of this pathogen, and will pursue the development of life-saving therapeutic and preventative advances with the assistance of NHMRC, MRFF and ARC grants. Professor Schembri has tracked the rapid emergence and global spread of a virulent, drug-resistant E. coli clone and used genome sequencing to understand its evolution and virulence.
Links: Professor Schembri collaborates with national and international research leaders, including in Denmark, where he was a lecturer. Professor Schembri has strong links with other international experts in his field, including at the Pasteur Institute and the Wellcome Trust Sanger Institute in Cambridge. His research collaborations also span lead groups at UQ and other top Australian institutes, including Griffith and La Trobe Universities.
Membership, Funding and patents: Since 2014, Professor Schembri has been awarded over $15 million in funding from competitive national research funding bodies. He holds provisional patents for the development of novel therapeutic agents and vaccine antigens. He is a Fellow of the American Academy of Microbiology, and is regularly invited to speak at international conferences in his field.
Awards and Communication: Professor Schembri was the recipient of the Frank Fenner Award (2010) and the ASM BacPath Oration Award (2019) for his outstanding original research contribution to the study of Infectious Disease. He was an Australian Research Council Future Fellow (2011-2015) a National Health and Medical Research Council Senior Research Fellow (2016-2020). Professor Schembri is the author of >240 peer-reviewed research manuscripts. He is President of the Australian Society for Microbiology (2022-2026).
Queensland Alliance for Agriculture and Food Innovation
Centre Director, Nutrition & Food S
Queensland Alliance for Agriculture and Food Innovation
Availability:
Available for supervision
Professor Yasmina Sultanbawa's research is focused within the agribusiness development framework, specifically in the area of food processing, preservation, food safety and nutrition. Her current research includes the minimisation of post harvest losses through value addition and the search for natural preservatives to replace current synthetic chemicals. In addition, her research area also includes the challenge of nutrition security, in particular micronutrient deficiency (hidden hunger), lack of diet diversity and nutritional losses in the food supply chain, which are addressed by her work with underutilized Australian plant species and potential new crops. Her work on Australian native plant foods is focused on incorporation of these plants in mainstream agriculture and diet diversification Working with indigenous communities to develop nutritious and sustainable value added products from native plants for use in the food, feed, cosmetic and health care industries is a key strategy. The creation of employment, economic and social benefits to these remote communities is an anticipated outcome. She considers it a privilege to engage with these communities and is very passionate that her work will have a positive socio-economic impact.
Research Focus
Functional ingredients (natural additives)
Functional food/feed/nutraceutical ingredients with enhanced nutritional and phytochemical profiles are obtained from specialty crops (Australian native plant foods) and industry co/by-products. Natural additives are obtained from raw materials of vegetable, fruit, herbs/spices or microbiological origin. An example is plant extracts which can provide e.g. antioxidants, shelf-life extension (natural antimicrobials), trace-nutrients (vitamins/ minerals) and novel flavours. Innovative technology solutions
Novel packaging systems
Development of active, biodegradable packaging material with natural additives for shelf life extension, smart packaging with nanosensors for the effective detection of food contaminants, microperforated packaging systems with optimised modified atmospheres for fresh foods and high barrier packaging material for herbs and spices are practical objectives of her research. Engineered nano-delivery systems for plant bioactives Develop nano-platforms for targeted delivery and controlled release of plant bioactives including antioxidant and antimicrobial products, through testing of in vitro activities and shelf life under various conditions.
Photodynamic treatment
Photodynamic treatment or photosensitization is a novel light and photo dye based approach which offers promising alternatives to conventional methods for the control of microorganisms. Plant bioactives such as curcumin has been successfully used to control mycrotoxigenic fungi. This technology has potential as a decontamination tool to reduce the microbial load in food and feed.
Food safety
Her research focus in this field includes intervention strategies to inhibit and prevent food-borne pathogens and spoilage organisms in fresh food and beverages, elucidating mechanisms of antimicrobial action, shelf-life extension with natural antimicrobials, retaining bioactivity during processing and storage, search for natural inhibitors from Australian native plants, use of bioactive honey from Leptospermum polygalifolium (Jelly bush) in treating microbial wound infections.
Professor Rachel Thomson is a Head of the Greenslopes Clinical Unit, Thoracic Physician and clinical researcher working at Greenslopes Private Hospital.
She has an international reputation in the area of Pulmonary Nontuberculous mycobacterial disease. She has published widely in the area and is regularly invited to speak at international and national meetings.https://medical-school.uq.edu.au/research/ntm-research-group
Her current research focuses on immunological and environmental aspects of susceptibility to NTM infection, characteristics of the lung and gut microbiome in NTM, and improving treatment outcomes.
In a clinical capacity, Professor Thomson is able to offer patients expert management of their disease at Pulmedica, Greenslopes Private Hospital, at public clinics at The Prince Charles Hospital and the MetroSouth Clinical TB service of the Princess Alexandra Hospital and via telehealth for patients across Australia. Patients can also access novel treatments through clinical trials in both the private and public sector.
Prof Thomson also has a special interest in respiratory problems of the elite athlete. This includes asthma management, vocal cord dysfunction, and the requirements of national and international doping organisations for asthma medications.
Associate Professor West is a molecular microbiologist, expert in bacterial pathogenesis. He is Head of “Tuberculosis Research” in the School of Chemistry and Molecular Biosciences, University of Queensland. Nick has a particular interest in drug development for TB. His research utilises modern molecular technologies to identify the genetic requirements for Mycobacterium tuberculosis to cause Tuberculosis (TB) with these genetic discoveries translated into novel antibiotic therapies. Research within his group falls largely into one of the following four themes: Essential Gene Identification in M. tuberculosis, Understanding TB Latency, Targeted TB Drug Development and Improving TB Vaccination.
Nick conducted postdoctoral research at the University of Oxford and Imperial College London. Returning to Australia in 2004, he spent several years at Sydney’s Centenary Institute as an Associate Faculty member before relocating to University of Queensland in 2012. In addition to drug development, Nick’s research portfolio includes programmes of vaccine and diagnostic development and testing.
Office of the Deputy Vice-Chancellor (Research and Innovation)
Affiliate Professor
Australian Institute for Bioengineering and Nanotechnology
Availability:
Available for supervision
Molecular virology.
My group's research interests encompass the molecular biology and immunopathology of medically important viral infections including Ebola. Current studies are focussed on two different viruses; dengue virus, a serious mosquito-borne disease in many tropical countries, and Respiratory Syncytial Virus (RSV), a major cause of hospitalization of children with respiratory infections.
The primary goals of our research are the development of vaccine and anti-viral strategies for the control of infections as well as a clearer understanding of the pathogenesis of severe disease.
Current projects in my laboratory include:
Structural biology based studies on the dengue virus proteins, NS3 (the viral protease) and E (a virion surface protein involved in cell binding and entry) and the RSV protein F (the viral fusion protein) as targets for antiviral drug design
Sub-unit and DNA based vaccines for the dengue viruses
Molecular pathogenesis of severe dengue disease (in particular, the consequences of dengue virus infection of host macrophages and the induction of mediators of vascular leak)
Design and delivery of ribozymes (catalytic RNAs) to the respiratory tract as an antiviral strategy for RSV infections
These projects involve the application of a range of techniques covering a number of disciplines including molecular biology, immunology, biotechnology, molecular cell biology, protein biochemistry and structural biology.
